Spots Global Cancer Trial Database for An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
Official Title: A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects
Study ID: NCT01932528
Conditions
Interventions
Study Description
Brief Summary: To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.
Detailed Description:
Keywords
Eligibility
Minimum Age: 30 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: Yes
Locations
Lexicon Investigational Site, Nottingham, , United Kingdom
Contact Details
Name: Doug Fleming, MD
Affiliation: Lexicon Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
